Lion Street Advisors LLC Buys 81 Shares of Abbott Laboratories $ABT

Lion Street Advisors LLC boosted its stake in shares of Abbott Laboratories (NYSE:ABT) by 2.2% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,749 shares of the healthcare product maker’s stock after purchasing an additional 81 shares during the quarter. Lion Street Advisors LLC’s holdings in Abbott Laboratories were worth $510,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Hughes Financial Services LLC bought a new stake in Abbott Laboratories during the first quarter worth approximately $27,000. Abound Financial LLC bought a new stake in Abbott Laboratories during the first quarter worth approximately $28,000. Elequin Capital LP bought a new stake in Abbott Laboratories during the first quarter worth approximately $30,000. JCIC Asset Management Inc. bought a new stake in Abbott Laboratories during the first quarter worth approximately $32,000. Finally, Vision Financial Markets LLC bought a new stake in shares of Abbott Laboratories in the first quarter valued at approximately $33,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Down 0.8%

Shares of ABT stock opened at $132.30 on Monday. The stock has a market cap of $230.26 billion, a P/E ratio of 16.58, a price-to-earnings-growth ratio of 2.51 and a beta of 0.69. Abbott Laboratories has a one year low of $110.86 and a one year high of $141.23. The stock has a fifty day moving average price of $132.54 and a 200 day moving average price of $131.60. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.01 billion. During the same period last year, the business earned $1.14 earnings per share. Abbott Laboratories’s quarterly revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be paid a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio is currently 29.57%.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.46% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on ABT shares. BTIG Research reduced their price objective on Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, July 18th. Royal Bank Of Canada increased their price objective on Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a research report on Tuesday, July 15th. The Goldman Sachs Group increased their price objective on Abbott Laboratories from $153.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday, October 1st. Jefferies Financial Group raised Abbott Laboratories from a “hold” rating to a “buy” rating and increased their price objective for the company from $143.00 to $145.00 in a research report on Friday, July 18th. Finally, Mizuho increased their price objective on Abbott Laboratories from $130.00 to $140.00 and gave the company a “neutral” rating in a research report on Wednesday, July 16th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $146.17.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.